The FDA's recent final rule on laboratory-developed tests (LDTs ... including those using complex or rare biological samples.

The FDA's final rule of LDTs includes a four-year phaseout to bring IVDs under its regulation, but there are obstacles.

Laboratories are just beginning to assess the magnitude of operational changes needed to comply with a new federal rule expanding regulatory oversight of lab developed tests (LDTs). In a major ...

Membraneless organelles, also called biomolecular condensates, are changing how scientists think about protein chemistry, ...

Hydra are a stand-out example of the phenomenon, but they aren’t necessarily unique in their resistance to time. A handful of ...

The laws vary widely from country to country, posing headaches for companies and complicating the sharing of biological ...

Membraneless organelles, also called biomolecular condensates, are changing how scientists think about protein chemistry, ...

Pioneer Fellow Hao Liu uses lasers to produce microfilament structures to grow biological tissue in the lab for research and ...

The researchers created several different anti-Bredt olefins by making silyl precursors and then carrying out an elimination ...

Binance Labs has made its first foray into the Decentralized Science (DeSci) sector with an investment in BIO Protocol (BIO), ...

The Centre has notified new Biological Diversity Rules to implement amended laws that fast-track research, support Indian traditional medicine, attract foreign investment, and exempt certain ...

On October 29, 2024, the Department of Justice (“DOJ”) published its Notice of Proposed Rulemaking (“NPRM”) to implement ...